Haemoblastoma

Title Study Year Journal/Event
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma – a phase II trial.

Mey UJM, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, et al. Br J Haematol. 2016 DOI: 10.1111/bjh.14481.

BRd 2016 Br J Haematol
Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with Non-Hodgkin-Lymphoma (NHL): results from an interim analysis of the non-interventional study NADIR.

Fietz T, Wolff T, Schulz H, Sandner R, Reichert D, Hurtz H-J, et al. Oncol Res Treat. 2016;39 (suppl5)(P950):xx.

NADIR 2016 DGHO
1st -line treatment of patients with mantle cell lymphoma: Treatment reality and first outcome data from the German prospective TLN Registry.

Knauf W, Bertram, Fietz T, Kirste T, Grugel R, Schnitzler, et al. Oncol Res Treat. 2016;39 (suppl5)(V364):

TLN 2016 DGHO
Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.

Becker M, Tschechne B, Reeb M, Schwinger U, Bruch H-R, Frank M, et al. Ann Hematol. 2015;94(9):1553–8

Be-1st 2015 ANN Hematol
1st-line treatment of patients with high-grade non-Hodgkin’s lymphoma: Similar effectiveness with R-CHOP-14 or R-CHOP-21 – Data from the German prospective TLN Registry.

Knauf W, Abenhardt W, Mohm J, Rauh J, Grugel R, Harde J, et al. Oncol Res Treat. 2015;38 (suppl 5)(V75):19.

TLN 2015 DGHO
Piaza: Non-interventional Study on Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMML (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder.

Wehmeyer J, Zaiss M, Losem C, Schmitz S, Neidig C, Teichmann B, et al. Oncol Res Treat. 2015;38 (suppl 5)(P235):70.

PIAZA 2015 DGHO
Prophylactic treatment of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with NHL: Subgroup analysis of the non-interventional study NADIR.

Fietz T, Wolff T, Sandner R, Janssen J, Hurtz H-J, Heits F, et al. Oncol Res Treat. 2015;38 (suppl 5)(P256):78.

NADIR 2015 DGHO
Revlimid-NIS: Non-interventional study on therapy of relapsed/ refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone.

Knauf W, Aldaoud A, Maintz C, Groschek M, Teichmann B, Harde J, et al. multiple myeloma with a combination of Lenalidomide plus Dexamethasone. Oncol Res Treat. 2015;38 (suppl 5)(P783):238.

Revlimid-NIS 2015 DGHO
1st-line treatment with R-CHOP-14 or R-CHOP-21 in patients with high-grade non-Hodgkin’s lymphoma is similarly effective: Data from the German prospective TLN Registry.

Knauf WU, Abenhardt W, Mohm J, Rauh J, Grugel R, Harde J, et al. Blood. 2014;124(21):4406.

TLN 2014 ASH
Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in routine clinical practice: Interim analysis of the German non-interventional study Be-CeLL1st.

Bruch H-R, Aldaoud A, Klausmann M, Hansen R, Losem C, Frank M, et al. Haematologica. 2014;99 (suppl 1)(PB1504).

Be-Cell 1st 2014 EHA
Treatment of non-transplant patients with multiple myeloma: Routine treatment by office-based haematologists in Germany – Data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).

Knauf W, Abenhardt W, Aldaoud A, Nusch A, Grugel R, Münz M, et al. Oncol Res Treat. 2014;37(11).

TLN 2014 Oncol ResTreat
Multiples Myelom und Neurotoxizität aus Sicht des Patienten und des Arztes: Ergebnisse des prospektiven Tumorregisters Lymphatische Neoplasien und des LyTox-Projektes.

Hurtz, H.-J., Knauf, W., Hutzschenreuter, U., Mittermüller, J., Grugel, R., Harde, J., Boller, E., Hartmann, H., Marschner, N Oncol Res Treat. 2014;37 (suppl 5)(P861).

TLN 2014 DGHO
Erstlinienbehandlung von Patienten mit Chronischer Lymphatischer Leukämie mit BR oder FCR: Erste Verlaufsdaten aus dem prospektiven Tumorregister Lymphatische Neoplasien.

Knauf, W., Abenhardt, W., Engel, E., Grugel, R., Harde, J., Jänicke, M., Marschner, N. Oncol Res Treat. 2014;37 ( suppl5)(P186).

TLN 2014 DGHO
Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in treatment routine: Interim results of the non-interventional study Be-Cell1st [Bendamustin-basierte erstlininetherapie bei chronischer lymphatischer Leukämie (CLL) – Zwischenergebnisse der nicht interventionellen Studie Be-Cell 1st].

Submitted to DGHO. 2014; Bruch H-R, Aldaoud A, Klausmann M, Hansen R, Losem C, Frank M, u. a. OncolResTreat 2014; 37(suppl.5)(P194)

Be-Cell 1st 2014 DGHO
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany – data from the Prospective Tumour Registry Lymphatic Neoplasms.

Knauf W, Abenhardt W, Dörfel S, Meyer D, Grugel R, Münz M, u. a. Hematol Oncol. 1. April 2014; DOI: 10.1002/hon.2139.

TLN 2014 Hematol Oncol
Response to 1st-line Treatment with BR or R-CHOP in Patients with Indolent non-Hodgkin’s Lymphoma: First Outcome Data from the German Prospective TLN Registry.

Knauf W, Abenhardt W, Hansen R, Grugel R, Harde J, Marschner N. Blood (ASH Annual Meeting Abstracts). 2013;122(21):3036.

TLN 2013 ASH
Response to 1st-line Treatment with BR or FCR in Patients with Chronic Lymphocytic Leukaemia: First Outcome Data from the German Prospective TLN Registry.

Knauf W, Abenhardt W, Engel E, Grugel R, Harde J, Marschner N. Blood (ASH Annual Meeting Abstracts). 2013;122(21):4181.

TLN 2013 ASH
Therapy of relapsed/ refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone: First interim analysis of the non-interventional study “Revlimid”.

Knauf W, Aldaoud A, Groschek M, Teichmann B, Harde J, Hasskarl J. Onkologie. 2013;36 (suppl. 7)(P532):155.

Revlimid-NIS 2013 DGHO
Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder): First interim analysis of the non-interventional study PIAZA.

Wehmeyer J, Zaiss M, Losem C, Schmitz S, Teichmann B, Harde J, u. a. Onkologie. 2013;36 (suppl. 7)(P797).

PIAZA 2013 DGHO
VMP in 1st-Line Treatment of Non-Transplant Patients with Multiple Myeloma in Routine Practice: First Follow-Up Data from the Tumour Registry Lymphatic Neoplasms.

Knauf W, Abenhardt W, Harich H-D, Schlag R, Grugel R, Marschner N. Onkologie. 2013;(P528).

TLN 2013 DGHO
Non-interventional study Be-1st: First line therapy with bendamustine in advanced indolent non-Hodgkin lymphoma (NHL) in treatment routine.

Becker M, Tschechne B, Reeb M, Schwinger U, Bruch H-R, Straßl L. haematologica. 2013;98(s1):P321.

Be-1st 2013 EHA
Treatment of Indolent NHL by Office-Based Haematologists in Germany: R-Bendamustine Replaces R-CHOP as „Standard of Care“.

Knauf W, Abenhardt W, Nusch A, Grugel R, Marschner N. Hematol Oncol. 2013;31 (Suppl. I)(Abstract 372):219.

TLN 2013 ICML
Treatment of Elderly Patients with CLL: Does Bendamustine Replace Chlorambucil as „Standard of Care“?

Knauf W, Abenhardt W, Nusch A, Grugel R, Marschner N. Hematol Oncol. 2013;31 (Suppl. I)(Abstract 467):248.

TLN 2013 ICML
Changes in German oncology outpatient centres of indolent non-Hodgkin lymphoma and chronic lymphocytic leukaemia in German haematology outpatient centres: Data from the clinical TLN Registry.

Knauf W, Abenhardt W, Nusch A, Grugel R, Marschner N. Onkologie. 2012;35 (Suppl.6)(P724):215.

TLN 2012 DGHO
Epidemiologisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten bei behandlungsbedürftigen malignen lymphatischen Systemerkrankungen der Tumorentitäten Non-Hodgkin-Lymphome, Chronische Lymphatische Leukämie und Multiples Myelom.

Knauf W. Myelom-Kongress, Starnberger See; 2012.

TLN 2012 Myelom-Kongress
Erst-Präsentation – über 1.000 dokumentierte Lymphom-Patienten: Aktuelle Daten und Diskussion [unveröffentlichte Daten aus dem Lymphom-Register].

Abenhardt W. Bendamustin-Symposium, Jena; 2012

TLN 2012 Bendamustin-Symposium
Bendamustine-Rituximab (BR) Replaces R-CHOP As „Standard of Care“ in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres.

Knauf WU, Abenhardt W, Nusch A, Grugel R, Marschner N. Blood (ASH Annual Meeting Abstracts). 2012;120(21):3666

TLN 2012 ASH
Bendamustine Replaces Chlorambucil As „Standard of Care“ in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres.

Knauf WU, Abenhardt W, Nusch A, Grugel R, Marschner N. Blood (ASH Annual Meeting Abstracts). 2012;120(21):4605.

TLN 2012 ASH
Tumorregister Lymphatische Neoplasien – Ausgewählte Analysen.

Abenhardt W. München; 2012.

TLN 2012 Lymphom-Meeting
Treatment of patients with Multiple Myeloma Routine treatment by office-based haematologists in Germany – Data from the Tumour Registry Lymphatic Neoplasms [Internet].

Hartmann H, Knauf W, Abenhardt W, Aldaoud A, Lerchenmüller C, Koska M. Madrid; 2011.

TLN 2011 ISPOR
Tumorregister Lymphatische Neoplasien (TLN) der niedergelassenen Hämato-/Onkologen in Deutschland.

Abenhardt W, Knauf W. München; 2011.

TLN 2011 Lymphom-Meeting
First line therapy with Bendamustine in advanced indolent Non-Hodgkin Lymphoma in treatment routine – interim analysis of the non-interventional study Be-1st.

Becker M, Tschechne B, Reeb M, Schwinger U, Grass J, Straßl L. Onkologie. 2011;34 (Suppl.6)(Poster P891):268.

Be-1st 2011 DGHO
Age-dependent differences in treatment of patients with Multiple Myeloma and Chronic Lymphocytic Leukaemia in outpatient cancer centres in Germany. Data from a clinical registry – TLN Registry.

Knauf W, Abenhardt W, Aldaoud A, Lerchenmüller C, Koska M, Marschner N. Onkologie. 2011;34 (Suppl.6)(V118):21.

TLN 2011 DGHO
Tumorregister Lymphatische Neoplasien – Klinisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten bei behandlungsbedürftigen malignen lymphatischen Systemerkrankungen der Tumorentitäten Non-Hodgkin-Lymphome, Chronische Lymphatische Leukämie und Multiples Myelom.

Knauf W, Abenhardt W. 2011.

TLN 2011 CLL-Studientreffen
Epidemiologisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten bei behandlungsbedürftigen malignen lymphatischen Systemerkrankungen der Tumorentitäten Non-Hodgkin-Lymphome, Chronische Lymphatische Leukämie und Multiples Myelom.

Knauf W, Abenhardt W. Heidelberg; 2011.

TLN 2011 Myelom-Kongress
How to Treat Chronic Lymphocytic Leukemia? Data From a Clinical Registry by Office-Based Hematologists in Germany (TLN Registry).

Knauf W, Abenhardt W, Aldaoud A, Lerchenmuller C, Koska M, Marschner N. Blood (ASH Annual Meeting Abstracts). 2011;118(21):4606.

TLN 2011 ASH
Treatment of patients with lymphatic B-cell neoplasia (TLN-Registry): A “Real Life” treatment overview in outpatient, office-based cancer centres in Germany.

Knauf W, Abenhardt W, Aldaoud A, Lerchenmüller C, Nacak T. Onkologie. 2010;33, Sup. 6:132

TLN 2010 DGHO
Bendamustine in the treatment of chronic lymphocytic leukemia.

Knauf W. Expert Rev Anticancer Ther. 2009 Feb;9(2):165–74.

02CLLIII 2009 Expert Rev Anticancer Ther
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Knauf W, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, u. a. J. Clin. Oncol. 2009 Sep 10;27(26):4378–84.

02CLLIII 2009 J Clin Oncol
Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: An updated analysis from an international phase III study. Blood (ASH Annual Meeting Abstracts).

Knauf W., Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, u. a. 2008 Nov 16;112(11):2091.

02CLLIII 2008 ASH
Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.

Knauf W., Lissichkov T, Aldaoud A, Herbrecht R, Liberati AM, Loscertales J, u. a.Blood (ASH Annual Meeting Abstracts). 2007 Nov 16;110(11):2043.

02CLLIII 2007 ASH

Merken

iOMEDICO AG
Hanferstraße 28
D-79108 Freiburg

Phone: 0761 - 15 242 0
E-Mail: info@iomedico.com